Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia
暂无分享,去创建一个
Praphan Phanuphak | Jintanat Ananworanich | Stephen J. Kerr | David A. Cooper | David P. Wilson | Alexander Hoare | J. Ananworanich | K. Ruxrungtham | D. Cooper | P. Phanuphak | S. Kerr | M. Law | Kiat Ruxrungtham | Matthew G. Law | A. Hoare | D. Wilson
[1] Praphan Phanuphak,et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010 , 2010 .
[2] D. Pillay,et al. Transmission of HIV-1 drug resistance. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[3] Wiwat Rojanapithayakorn,et al. The 100% Condom Use Programme in Asia , 2006, Reproductive health matters.
[4] K. Ruxrungtham,et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor‐naïve, nonnucleoside reverse transcriptase inhibitor‐experienced patients: study TMC125‐C227 * , 2008, HIV medicine.
[5] T Brown,et al. The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia , 2004, Sexually Transmitted Infections.
[6] K. Ruxrungtham,et al. High Rate Multiple Drug Resistances in HIV-Infected Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Thailand, Where Subtype A/E is Predominant , 2006, Journal of the International Association of Physicians in AIDS Care.
[7] Sung Soon Kim,et al. National Survey for Drug-Resistant Variants in Newly Diagnosed Antiretroviral Drug-Naive Patients With HIV/AIDS in South Korea: 1999-2005 , 2008, Journal of acquired immune deficiency syndromes.
[8] Hsin-Yun Sun,et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. , 2008, The Journal of antimicrobial chemotherapy.
[9] D. Bangsberg,et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. , 2004, The Journal of infectious diseases.
[10] K. Ruxrungtham,et al. HIV drug resistance transmission threshold survey in Bangkok, Thailand , 2008, Antiviral therapy.
[11] A. Apisarnthanarak,et al. Antiretroviral drug resistance among antiretroviral‐naïve persons with recent HIV infection in Thailand , 2008, HIV medicine.
[12] A. Geretti,et al. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.
[13] Erin N. Bodine,et al. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.
[14] M. Law,et al. Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD) , 2007, AIDS research and therapy.
[15] Anne-Mieke Vandamme,et al. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[16] W. Sugiura,et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. , 2007, Antiviral research.
[17] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[18] C. Boucher,et al. Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 1999, Journal of Clinical Microbiology.
[19] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[20] U. Siangphoe,et al. National Expansion of Antiretroviral Treatment in Thailand, 2000-2007: Program Scale-Up and Patient Outcomes , 2009, Journal of acquired immune deficiency syndromes.
[21] P. Harrigan,et al. Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.
[22] P. Harrigan,et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.
[23] T. Brown,et al. HIV/AIDS in Asia , 2003, The Lancet.
[24] D. Kempf,et al. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. , 2005, The Journal of infectious diseases.
[25] A. Zolopa,et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations , 2003, AIDS.
[26] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[27] Sally Blower,et al. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. , 2003, Current drug targets. Infectious disorders.
[28] S. Blower,et al. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban–rural divide , 2006, Proceedings of the National Academy of Sciences.
[29] Sa Azin,et al. An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .
[30] F. Maggiolo,et al. Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.
[31] Organización Mundial de la Salud,et al. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .
[32] Y. Lo,et al. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. , 2006, The Southeast Asian journal of tropical medicine and public health.
[33] A. Vibhagool,et al. The TREAT Asia HIV Observational Database: Baseline and Retrospective Data , 2005, Journal of acquired immune deficiency syndromes.
[34] T. Puthanakit,et al. Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy , 2009, The Pediatric infectious disease journal.
[35] B. Gazzard,et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study , 2007, The Lancet.
[36] K. Ungchusak,et al. The epidemiology of HIV infection and AIDS in Thailand. , 1991, AIDS.
[37] Wasun Chantratita,et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] K. Fennie,et al. Adherence to Antiretroviral Medication Among HIV-Positive Patients in Thailand , 2006, Journal of acquired immune deficiency syndromes.
[39] P. Harrigan,et al. The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes , 2008, Journal of acquired immune deficiency syndromes.
[40] R. Schooley,et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] P. Harrigan,et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.
[42] D. Ho,et al. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.
[43] A. Apisarnthanarak,et al. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. , 2008, Clinical Infectious Diseases.
[44] Hadi Dowlatabadi,et al. Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .
[45] James Curran,et al. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .
[46] Julio S. G. Montaner,et al. Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.
[47] Matthew G Law,et al. Relation between HIV viral load and infectiousness: a model-based analysis , 2008, The Lancet.
[48] G. Cohen. Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries , 2007, AIDS.
[49] J. H. Chen,et al. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[50] David P Wilson,et al. Sampling and sensitivity analyses tools (SaSAT) for computational modelling , 2008, Theoretical Biology and Medical Modelling.
[51] M. S. Sánchez,et al. A decrease in drug resistance levels of the HIV epidemic can be bad news , 2005, Bulletin of mathematical biology.
[52] B. Gazzard,et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.
[53] Rodolphe Thiébaut,et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.
[54] Matthias Egger,et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.